
    
      This is a multicenter, randomized, double-blind, parallel group, chronic dosing,
      active-controlled, 28-week, safety extension of Study PT010006 to assess the safety and
      efficacy of BGF MDI, GFF MDI, BFF MDI, and Symbicort TBH as an active control over a 52-week
      period in Japanese subjects with moderate to very severe COPD who remain symptomatic on
      maintenance treatment with either an ICS and one or more bronchodilator(s) or two or more
      maintenance bronchodilators.
    
  